Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer

Authors

Beomyoung Cho, University of North FloridaFollow
Maria Pérez, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Donna B. Jeffe, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Matthew W. Kreuter, The Brown School, Washington University, Saint Louis, MO, USA.
Julie A. Margenthaler, Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA.
Graham A. Colditz, Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA.
Ying Liu, Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO, USA. yliu3@wustl.edu.

Document Type

Article

Publication Date

8-1-2022

Subject Area

Antineoplastic Agents, Hormonal (therapeutic use); Breast Neoplasms (drug therapy, pathology); Female; Humans; Obesity; Postmenopause; Receptor, ErbB-2

Abstract

BACKGROUND: Despite benefits of endocrine therapy (ET) for patients with hormone-receptor (HR)-positive breast cancer, many patients do not initiate or discontinue ET against recommendations. METHODS: We identified variables associated with ET initiation and continuation, analyzing pooled data from two longitudinal studies at a National Cancer Institute comprehensive cancer center in St. Louis, Missouri. The sample included 533 women with newly diagnosed, non-metastatic, HR-positive breast cancer who completed interviews at enrollment and 6, 12, and 24 months after definitive surgical treatment. Logistic regression models estimated the adjusted odds ratio and 95% confidence interval (aOR [95% CI]) for each of self-reported ET initiation by the 12-month interview and continuation for ≥12 months by the 24-month interview in association with self-reported diabetes, elevated depressed mood, menopausal-symptom severity and obesity, adjusting for race, age, insurance status, chemotherapy, and radiation therapy. RESULTS: Overall, 81.4% (434/533) of patients initiated ET, and 86.5% (371/429) continued ET ≥12 months. Patients with diabetes had lower odds of initiating ET (0.50 [0.27-0.91]). Patients reporting greater menopausal-symptom severity had lower odds of continuing ET (0.72 [0.53-0.99]). CONCLUSION: Efforts to increase ET initiation among patients with diabetes and better manage severe menopausal symptoms among ET users might promote ET continuation. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov : #NCT00929084.

Publication Title

BMC cancer

Volume

22

Issue

1

First Page

837

Digital Object Identifier (DOI)

10.1186/s12885-022-09946-x

PubMed ID

35915419

E-ISSN

1471-2407

Language

eng

Citation Information

Cho, Beomyoung; Pérez, Maria; Jeffe, Donna B.; Kreuter, Matthew W.; Margenthaler, Julie A.; Colditz, Graham A.; and Liu, Ying, "Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer" (2022). UNF Faculty Research and Scholarship. 3194.
https://digitalcommons.unf.edu/unf_faculty_publications/3194